Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × vistusertib × Lymphoid × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2 Breast 2 Tumor-Agnostic 1 Lymphoid 1 CNS 1

Conditions

Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

Cyclophosphamide 191 Rituximab 178 fludarabine 116 fludarabine phosphate 81 Vincristine 71 Etoposide 61 Cytarabine 58 Doxorubicin 56 Lenalidomide 54 Dexamethasone 52 venetoclax 51 ibrutinib 51 Prednisone 51 obinutuzumab 45 Bendamustine Hydrochloride 44 Filgrastim 41 Bortezomib 37 Specimen Handling 36 Melphalan 35 Gemcitabine 34 pembrolizumab 33 Methotrexate 33 Biopsy 32 Magnetic Resonance Spectroscopy 30 Nivolumab 29 Vorinostat 28 Peripheral Blood Stem Cell Transplantation 28 Azacitidine 28 Calcium Dobesilate 25 Clofarabine 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡